Today is Saint David’s day and I should be showing a picture of a bunch of daffodils (National Flower of Wales, in addition to the Leek), but instead you get a bunch of tulips for MsMouse
If you want to ask a question this is the place for you.
Today is Saint David’s day and I should be showing a picture of a bunch of daffodils (National Flower of Wales, in addition to the Leek), but instead you get a bunch of tulips for MsMouse
If you want to ask a question this is the place for you.
Letter by British Rhinological Society and Ear, Nose & Throat UK Although severe acute respiratory syndrome (SARS) has been the hallmark of severe COVID19 infection, anosmia (lack of smell) and hypogeusia (the reduced ability to taste), headaches/dizziness have also been reported. Is COVID19 neurotropic? We don’t have hard data to support/refute this beyond history from those so far...
If you live in the UK and have MS you may receive a letter from the NHS stating that you are potentially in the ‘extremely vulnerable group’ in relation to COVID-19. The reason for that is they are using GP databases and other sources of information to identify patients who may be on immunosuppressive therapy. If you receive one of these letters don’t be alarmed and please...
The ABN is saying natlaizumab is OK, but have they thought about the science? ProfG has asked if there is a literature on neurotrophism from coronavirus? If there is would you inhibit surveillance. This is not unknown for this type of virus…food- for thought. But the main route of entry of COVID-19 into cells is via the ACE-2 receptor. This is very low in the CNS in humans. source Brainseq...
Who reviews this stuff? I am not going to give this paper the dignity of an citation to you to help the altmetric, but part of our job is to call poor animal experiments. However, this is one of the reasons why EAEologists are living on borrowed time and if COVID-19 does not get them, then any ethical review panel should. This is where international Societies have to step up to the plate and...
Comparison of rituximab originator (MabThera®) to biosimilar (Truxima®) in patients with multiple sclerosis. Perez T, Rico A, Boutière C, Maarouf A, Roudot M, Honoré S, Pelletier J, Bertault-Peres P, Audoin B. Mult Scler. 2020 Mar 17:1352458520912170. BACKGROUND:Rituximab’s originator MabThera® or Rituxan® has demonstrated high efficacy in multiple sclerosis (MS). Because of the patent...
The impact of COVID-19 in multiple sclerosis: a substudy of the UK MS Register We need to understand more about COVID-19 urgently, and you can help. COVID-19, the coronavirus infection, is devastating the health and jobs of millions around the world, and is now in increasing in the UK with a major impact on all of our lives. People with multiple sclerosis (pwMS) are a susceptible group both due...
In my inbox this morning there were several emails from people with MS asking the same questions. What should I do; self-isolate or continue as is? Should I stop my DMT or continue it? Am I at increased risk of COVID-19 or not? If I get COVID-19 am I at risk of developing serious disease? Should I purchase a ventilator? I have symptoms of COVID-19 what should I do? Are there any patients with MS...
I was one the train a few days a go listening to a bloke on the phone to his mate. He thought because he had the flu vaccine enough times so he was immune to the covid-19 causing virus…Luckily for them they were young enough that they will probably survive their misconsceptions, but for our parents and grand parents, this attitude is what will send some of us to our makers…Funny I...
The yin and yang of COVID-19. I have spent day 2 of London’s lockdown doing MS-related webinars; i.e. attending meetings virtually. For every negative, there is a positive, the yin-and-yang of COVID-19. Environmental activists are claiming SARS-CoV2/COVID19 is simply nature’s way of fighting back. We have pushed planet earth and its environment to the brink and it is responding as...
If you are a HCP professional you may be interested to read the experience of some HCP from China. The handbook focuses on the real-time hotspots of the COVID-19 epidemic. It provides detailed and comprehensive answers to potential questions for diagnosing and treating patients in different types. Treatment methods to treat the critically ill Efficient clinical decision-making strategies for...